Adrenergic beta-agonist: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 7: | Line 7: | ||
===Chronic obstructive pulmonary disease=== | ===Chronic obstructive pulmonary disease=== | ||
:''See [[chronic obstructive pulmonary disease]]'' | :''See [[chronic obstructive pulmonary disease]]'' | ||
[[Image:SMART study 2006.jpg|right|thumb|350px|{{#ifexist:Template:SMART study 2006.jpg/credit|{{SMART study 2006.jpg/credit}}<br/>|}}Effect of LABAs on asthma-related mortality, controlling for race and use concommitent steroids.]] | |||
Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with [[corticosteroid]]s.<ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref> | Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with [[corticosteroid]]s.<ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref> | ||
Revision as of 22:08, 16 September 2008
Adrenergic beta-agonists (beta-agonists) are "drugs that selectively bind to and activate beta-adrenergic receptors."[1]
Medical uses
Asthma
- See asthma
Chronic obstructive pulmonary disease
Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with corticosteroids.[2]
Drug toxicity
Long acting adrenergic beta-agonists (LABA) associated with may adverse outcomes among patients with asthma when used without corticosteroids and maybe among African American patients.[3] They might be safe in asthma as long as corticosteroids are used. According to a meta-analyses by the Cochrane Collaboration, when used with corticosteroids the relative risk for asthma-related death is increased at 1.34 although this increase was not statistically significant with a confidence interval of 0.30 to 5.97.[4][5] There are two major randomized controlled trials of LABAs.[6][7]
References
- ↑ Anonymous (2024), Adrenergic beta-agonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R (May 2008). "Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review". Chest 133 (5): 1079–87. DOI:10.1378/chest.07-1167. PMID 18460518. Research Blogging.
- ↑ Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (2006). "Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths". Ann. Intern. Med. 144 (12): 904-12. PMID 16754916. [e]
- ↑ Walters EH, Gibson PG, Lasserson TJ, Walters JA (2007). "Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid". Cochrane Database Syst Rev (1): CD001385. DOI:10.1002/14651858.CD001385.pub2. PMID 17253458. Research Blogging.
- ↑ Cates CJ, Cates MJ (2008). "Regular treatment with salmeterol for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006363. DOI:10.1002/14651858.CD006363.pub2. PMID 18646149. Research Blogging.
- ↑ Castle W, Fuller R, Hall J, Palmer J (April 1993). "Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment". BMJ 306 (6884): 1034–7. PMID 8098238. PMC 1676982. [e]
- ↑ Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM (January 2006). "The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol". Chest 129 (1): 15–26. DOI:10.1378/chest.129.1.15. PMID 16424409. Research Blogging.